Por: Fox Business Business April 03, 2023
Check out whats clicking on FoxBusiness.com The on Monday ordered life sciences company Illumina to unwind its $7.1 billion acquisition of cancer detection test developer Grail Inc., citing antitrust concerns. The commission voted unanimously in a 4-0 decision to force Illumina to divest from Grail, reversing a decision from the FTC's own chief administrative law judge from Sept. 2022, which had dismissed the antitrust charges. The Federal... + full article
The Boston Globe USA Business April 04, 2023
Illumina Inc. was ordered to unwind its $7 billion acquisition of cancer startup Grail by the Federal Trade Commission, an uncommon move by antitrust regulators who said the deal raises competition concerns for cancer testing.The FTC’s 4-0 decision announced Monday overturned... + más
FTC orders Illumina to unwind $7B deal for cancer test developer Grail | Fox Business
Biotech company Illumina pushes back against Carl Icahn’s proxy fight over $7.1 billion Grail deal | CNBC
The New York Times USA Business April 03, 2023
The Federal Trade Commission on Monday ordered Illumina, the leading maker of gene-sequencing machines, to divest Grail, a cancer-test developer.The move by the F.T.C. is the latest development in a case seen by antitrust experts as a to stop big companies from buying fledgling... + más
CNBC USA Health March 24, 2023
In this articleCarl Icahn speaking at Delivering Alpha in New York on Sept. 13, 2016.David A. Grogan CNBCCarl Icahn on Friday alleged that 's directors demanded extra personal liability insurance before the biotech company signed off on a $7.1 billion acquisition of cancer... + más
Icahn proposes three candidates for Illumina’s board — Here’s what could be next in the battle | CNBC
CNBC USA Health March 21, 2023
In this articleCarl IcahnAdam Jeffery CNBC Biotech company pushed back Monday against Carl Icahn's proxy fight over the company's acquisition of cancer test developer Grail, saying the activist investor's board nominees do not add value. The San Diego-based DNA... + más
Carl Icahn claims Illumina directors got extra insurance to close 'disastrous' $7.1 billion Grail deal | CNBC
CNBC USA Business March 18, 2023
Business: develops, manufactures and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and Grail. Grail, which was acquired in , is a health-care company focused on early detection of... + más
Los Angeles Times USA Business November 16, 2022
San Diego’s Illumina said this week that it will trim its global workforce by 5% amid economic headwinds that have slowed orders and are expected to linger into 2023. The gene sequencing market leader, which employs about 9,200 workers worldwide, declined to say how many... + más
The era of fast, cheap genome sequencing is here | Ars Technica
Illumina: Q4 Earnings Snapshot | Associated Press
Ars Technica USA Science October 01, 2022
Navigate Filter by topic Settings Front page layout Site theme Comment activity Sign up or login to join the discussions! Sign up to comment and more - Oct 1, 2022 11:17 am UTC / Illumina says its NovaSeq X machine will get the price of sequencing down to $200 per human... + más
The best budget laptop of 2022 | The Verge
Starting a Revolution Isn’t Enough | The Atlantic
About iurex | Privacy Policy | Disclaimer |